Impact ledger
ACM Research, Inc. (ACMR): the developments shaping its investment case
Follow the evidence affecting ACM Research, Inc.'s demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-06-22 | revenue | Bullish | Newly signed orders increased by 65% year-over-year in Q1 2026, supporting full-year revenue guidance of RMB 8.20 billion to RMB 8.80 billion. |
Event impact log
4 events mapped to ACMR since 2026-08-26. Evidence through 2026-09-02.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-02 | KraneShares registers Photonic and Optical ETF (LUMA) for Japan distribution | While not a direct optical component maker, ACM Research provides wafer processing equipment critical for semiconductor manufacturing, including advanced photonics. Increased investment in the sector could indirectly benefit equipment suppliers. | Bullish | 1-3m | 0.20 |
| 2026-09-02 | KraneShares completes Japan trust notification for LUMA Photonic and Optical ETF | potential for increased capital allocation to underlying holdings of the ETF, as a supplier to the broader semiconductor and optical industry | Bullish | 3-12m | 0.30 |
| 2026-09-02 | KraneShares registers Photonic and Optical ETF for distribution in Japan | Potential for increased indirect investment flow into underlying holdings of the LUMA ETF, including companies involved in semiconductor manufacturing equipment for optical components. | Bullish | 3-12m | 0.30 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | Increased investor interest in neurodegenerative disease drug development, potential for read-across from other pipeline successes/failures. | watch | 3-12m | 0.50 |
Continue this research
Build your ACM Research, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ACMR entity page →